News Release


 

Launch of Histamine H2 Receptor Antagonist PROTECADIN® OD Tablets (Orally Disintegrating Tablet) (22/06/2012)

Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo; President: Masayuki Kobayashi) announced today, Friday, June 22, that a National Health Insurance (NHI) price listing was established for PROTECADIN® OD Tablets 5 and PROTECADIN® OD Tablets 10, the additional dosage forms of its histamine H2 receptor antagonist PROTECADIN® Tablet (Lafutidine).
The new products are scheduled for launch on Tuesday, July 24.

PROTECADIN® Tablet has been proven to be effective against gastric and duodenal ulcers. It was launched in April 2000 in 5mg and 10mg doses. In March 2012 it was approved for the additional indication of reflux esophagitis.

PROTECADIN® Tablet can be taken orally without water and therefore satisfies a wide variety of patient needs. It is ideal for dysphagia patients, the elderly, and patients whose liquid intake is being restricted. It can also easily be taken when a patient is traveling and unable to drink or find drinking water.

 


<< Back